Long-term, randomized safety study of MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system) in subjects with chronic rhinitis.

Berger, William E; Shah, Shailen; Lieberman, Phil; Hadley, James; Price, David; Munzel, Ullrich; Bhatia, Sanjay

Berger, William E; Shah, Shailen; Lieberman, Phil; Hadley, James; Price, David; Munzel, Ullrich; Bhatia, Sanjay.

Affiliation

Berger WE; Allergy and Asthma Associates of Southern California, Mission Viejo, Calif. Electronic address: weberger@uci.edu.
Shah S; Allergy and Asthma Consultants of NJ-PA PC, Collegeville, Pa.
Lieberman P; University of Tennessee College of Medicine, Memphis, Tenn.
Hadley J; Specialty Care Center, Physicians Regional Medical Center, Naples, Fla.
Price D; University of Aberdeen, Aberdeen, UK; Royal Nose, Throat, and Ear Hospital, London, UK.
Munzel U; Meda Pharma GmbH & Co. KG, Bad Homburg, Germany.
Bhatia S; IRL-Synexus Clinical Research Centre, Chakala, Mumbai, India.

J Allergy Clin Immunol Pract ; 2(2): 179-85, 2014.

Article de En | MEDLINE | ID: mdl-24607046

Sujet(s)
Mots clés

Allergic rhinitis; Azelastine; Chronic rhinitis; Clinical trial; Fluticasone; Hypothalamic-pituitary-adrenal axis; Perennial allergic rhinitis; Vasomotor rhinitis

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Phtalazines / Rhinite / Rhinite spasmodique apériodique / Androstadiènes Type d'étude: Clinical_trials Limites: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Langue: En Journal: J Allergy Clin Immunol Pract Année: 2014 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google